Not testimonials, not "before and after" photos — the actual SURMOUNT trial data, by dose, so you know what's realistic before you start.
In SURMOUNT-1, 72 weeks of tirzepatide produced average weight loss of roughly 16% at the 5mg dose, 21% at 10mg, and 22.5% at the maximum 15mg dose — a clear dose-response relationship, not a fixed outcome.
Source: Jastreboff et al., New England Journal of Medicine, 2022 (SURMOUNT-1). Not medical advice — individual results vary; these are trial averages, not guarantees.
SURMOUNT-1 enrolled adults with obesity or overweight plus a weight-related condition, without diabetes. The separate SURMOUNT-5 head-to-head trial found tirzepatide outperformed semaglutide at 72 weeks, roughly −20% vs. −14% body weight — but head-to-head margins can differ from single-arm averages, so treat both figures as trial-specific, not universal.
Trial data shows a clear dose-response curve — people who titrate all the way to 15mg see larger average losses than those who stop lower.
72-week trial data reflects sustained treatment. Stopping early, or large gaps in dosing, generally means less cumulative effect.
These are averages across hundreds of trial participants — some people lose more, some less. Genetics, starting weight, and adherence all play a role.
Log your weight alongside every dose and shot — see your own curve next to what the trials predicted, not someone else's.
Because weight loss tracks with dose and time on treatment, the app keeps both on the same timeline automatically.
A clean export of weight, dose, and adherence — useful context if your results diverge from what you expected.
One email at launch · free trial · no credit card